Building on feedback and experience from prior models, LEAD aims to reduce barriers to success for both new and experienced ...
BARCELONA, Spain — Use of ravulizumab for long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) offered sustained protection from relapse for at least 3 years, results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results